Observing treatment patterns for atopic dermatitis patients using abrocitinib in Taiwan
The Real-world Treatment Patterns and Clinical Outcomes in Moderate-to-severe Atopic Dermatitis (AD) Patients Receiving Abrocitinib
This study looks at how well abrocitinib works for treating moderate-to-severe atopic dermatitis in patients aged 12 and older in Taiwan over a year.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 12 Years and up |
| Sex | All |
| Sponsor | Pfizer Industry-sponsored |
| Drugs / interventions | abrocitinib |
| Locations | 8 sites (Kaohsiung City and 7 other locations) |
| Trial ID | NCT06353087 on ClinicalTrials.gov |
What this trial studies
This observational study aims to describe the real-world treatment patterns and clinical outcomes of patients with moderate-to-severe atopic dermatitis (AD) who are newly prescribed abrocitinib over a 12-month period. It will collect data on patient demographics, baseline characteristics, and treatment responses in a real-world setting. The study will involve patients aged 12 years and older who meet specific inclusion criteria and will be conducted at multiple hospitals in Taiwan.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 12 years and older with a confirmed diagnosis of moderate-to-severe atopic dermatitis who are starting treatment with abrocitinib.
Not a fit: Patients who have previously used abrocitinib or are participating in another study involving investigational drugs will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness and safety of abrocitinib for treating moderate-to-severe atopic dermatitis in real-world settings.
How similar studies have performed: Other studies have shown success with similar observational approaches in understanding treatment patterns and outcomes for atopic dermatitis, making this study a valuable addition to existing knowledge.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. Patients aged ≥12 years 2. Patients with confirmed diagnosis of moderate-to-severe AD as assessed by the physician 3. Patients for whom the physician's decision has been made to newly prescribe abrocitinib in usual clinical practice conditions 4. Evidence of a personally signed and dated informed consent/assent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study Exclusion Criteria: Patients meeting any of the following criteria will not be included in the study: 1. Any prior use of abrocitinib 2. Simultaneous participation in a study that includes administration of any investigational drug or procedure
Where this trial is running
Kaohsiung City and 7 other locations
- Kaohsiung Medical University Hospital — Kaohsiung City, Taiwan (Not_yet_recruiting)
- Chang Gung Memorial Hospital at Kaohsiung — Kaohsiung City, Taiwan (Recruiting)
- Taipei Medical University - Shuang Ho Hospital — New Taipei City, Taiwan (Not_yet_recruiting)
- Ntuh — Taipei, Taiwan (Recruiting)
- MacKay Memorial Hospital — Taipei, Taiwan (Not_yet_recruiting)
- Taipei Veterans General Hospital — Taipei, Taiwan (Not_yet_recruiting)
- Tri-Service General Hospital — Taipei, Taiwan (Not_yet_recruiting)
- Chang Gung Hospital Linkou — Taoyuan, Taiwan (Not_yet_recruiting)
Study contacts
- Study coordinator: Pfizer CT.gov Call Center
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
- Phone: 1-800-718-1021
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.